# insilico.com

> AI-optimized mirror of insilico.com containing 481 pages totalling 273,021 words of clean markdown content, structured data, and semantic HTML. Original source: https://insilico.com. Last updated: 2026-07-26T04:01:51.893Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Main | Insilico Medicine](/content/site-root.html): Generative AI and Automation for Longevity and Sustainability (150 words)
- [Insilico Bench | Insilico Medicine](/content/insilicobench/index.html): Insilico Bench - Proprietary AI Benchmarks for Drug Discovery. Comprehensive benchmarks for LLMs in clinical trial prediction and target discovery. (380 words)
- [Drug Discovery Benchmark | Insilico Medicine](/content/ddb/index.html): Drug Discovery Benchmark - Public & Proprietary AI Benchmarks for Drug Discovery. Comprehensive benchmarks for LLMs in clinical trial prediction and target discovery. (402 words)
- [Insilico Science AI Bench | Insilico Medicine](/content/scienceaibench/index.html): Insilico Science AI Bench - Benchmarking AI Across the Sciences. Comprehensive benchmarks for LLMs in clinical trial prediction and target discovery. (314 words)

## Articles & Blog Posts

- [ir/media/elujlodg/insilico-dissemination-of-corporate-communications-final-pdf.html](/content/ir/media/elujlodg/insilico-dissemination-of-corporate-communications-final-pdf.html) (1,496 words)
- [ir/media/cfqejaym/terms-of-reference-for-the-remuneration-committee-e-pdf.html](/content/ir/media/cfqejaym/terms-of-reference-for-the-remuneration-committee-e-pdf.html) (1,615 words)
- [PowerPoint Presentation](/content/ir/media/x5infymc/ism_investor-deck_cn_20260715_wo-appendix-pdf.html) (658 words)
- [ir/media/ndlbwxmm/terms-of-reference-for-the-environmental-social-and-governance-committee-e-pdf.html](/content/ir/media/ndlbwxmm/terms-of-reference-for-the-environmental-social-and-governance-committee-e-pdf.html) (1,171 words)
- [ir/media/4dcozhor/e_ham25121426ann-20251228-20251228_2337-pdf.html](/content/ir/media/4dcozhor/e_ham25121426ann-20251228-20251228_2337-pdf.html) (597 words)
- [ir/media/sp3pnhpk/e_ham25121671ann-20251229-20251229_0030-pdf.html](/content/ir/media/sp3pnhpk/e_ham25121671ann-20251229-20251229_0030-pdf.html) (693 words)
- [ir/media/kk4iy20q/terms-of-reference-for-the-nomination-committee-e-pdf.html](/content/ir/media/kk4iy20q/terms-of-reference-for-the-nomination-committee-e-pdf.html) (650 words)
- [ir/media/2g2a2bn2/insilico-medicine-list-of-directors-and-their-role-and-function-en-pdf.html](/content/ir/media/2g2a2bn2/insilico-medicine-list-of-directors-and-their-role-and-function-en-pdf.html) (164 words)
- [ir/media/nzqppxjj/e_ham25121057ann-20251229-20251229_1449-pdf.html](/content/ir/media/nzqppxjj/e_ham25121057ann-20251229-20251229_1449-pdf.html) (35,906 words)
- [ir/media/vd3irjef/terms-of-reference-for-the-audit-committee-e-pdf.html](/content/ir/media/vd3irjef/terms-of-reference-for-the-audit-committee-e-pdf.html) (2,014 words)
- [ir/media/vxobrafh/ism_2025-earnings-deck_en-pdf.html](/content/ir/media/vxobrafh/ism_2025-earnings-deck_en-pdf.html) (571 words)
- [ir/media/xjej0d5k/ism_investor-deck_en_20260715_wo-appendix-pdf.html](/content/ir/media/xjej0d5k/ism_investor-deck_en_20260715_wo-appendix-pdf.html) (455 words)
- [PowerPoint Presentation](/content/ir/media/sdjbqxdx/ism_2025-earnings-deck_cn-pdf.html) (125 words)
- [404 | Insilico Medicine](/content/nach01/index.html) (103 words)
- [Corporate Governance | Insilico Medicine](/content/ir/en/corporate-governance/index.html) (1,360 words)
- [Investor Relations | Insilico Medicine](/content/ir/en/index.html) (375 words)
- [英矽智能发布2026年中期盈利预喜](/content/news_sc/j8bsfbsdm1-2026/index.html) (43 words)
- [PHD1/2 | Insilico Medicine](/content/pipeline_target_phd/index.html) (1,007 words)
- [Listing Documents | Insilico Medicine](/content/ir/en/information-disclosure/listing-documents/index.html) (7 words)
- [Using AI to Fight a Pandemic](/content/covid_pcc/index.html): Insilico Medicine Announces Novel Preclinical Candidate for COVID-19 Treatment (2,062 words)
- [404 | Insilico Medicine](/content/mmai/null/index.html) (122 words)
- [ir/media/qy4jdbtg/c_03696ann-20251229-20251229_0014-pdf.html](/content/ir/media/qy4jdbtg/c_03696ann-20251229-20251229_0014-pdf.html) (114 words)
- [Expanding the Immuno-oncology Toolbox with an AI-discovered Target and Novel Inhibitor | Insilico Medicine](/content/blog/immuno-oncology/index.html): Double Impact: Insilico Medicine Delivers Novel Immuno-Oncology Target and Preclinical Candidate Using AI (1,434 words)
- [AI Accelerates Race for New Synthetic Lethality Therapeutics| Insilico Medicine](/content/mat2a/index.html): AI Accelerates Race for New Synthetic Lethality Therapeutics (970 words)
- [404 | Insilico Medicine](/content/news_sc/rme4pmrno1-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e4-b8-8e-e4-bf-9d-e7-91-9e-e8-8d-af-e4-b8-9a-e7-ad-be-e7-bd-b2-e6-88-98-e7-95-a5-e5-90-88-e4-bd-9c-ef-bc-8c-e5-85-b1-e5-90-8c-e6-8e-a8-e8-bf-9b-e4-ba-ba-e5-b7-a5-e6-99-ba-e8-83-bd-e9-a9-b1-e5-8a-a8-e7-9a-84-e8-8d-af-e7-89-a9-e7-a0-94-e5-8f-91.html) (103 words)
- [Insilico Medicine Announces 2025 Annual Results, Redefining Value Delivery in AI-Powered Drug Discovery](/content/news/ohz9ozx0t1-insilico-medicine-announces-2025-annual/index.html) (1,548 words)
- [3CLpro | Insilico Medicine](/content/pipeline_target_3clpro/index.html) (462 words)
- [BIO Europe 2025 | Pushing the frontiers of generative AI for longevity, Insilico unveils portfolio of unique multiparameter-optimized cardiometabolic assets](/content/news/89a86bpg91-bio-europe-2025-pushing-the-frontiers-of.html) (1,402 words)
- [USP1 | Insilico Medicine](/content/pipeline_target_usp1/index.html) (630 words)
- [CDK12/13 | Insilico Medicine](/content/pipeline_target_cdk12/13/index.html) (402 words)
- [Environmental Sustainability Consortium](/content/sustainability/index.html): Our mission is to develop and promote open source cutting-edge generative AI technologies for environmental sustainability. (764 words)
- [英矽智能发布 LabClaw 智能实验室系统，引领药物研发从“自动化”迈向“自主化”](/content/news_sc/rgga92ofe1-labclaw/index.html) (99 words)
- [404 | Insilico Medicine](/content/news_sc/yzx9caigt1-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e4-bb-bb-e5-91-bd-e7-8e-8b-e7-8f-8f-e5-8d-9a-e5-a3-ab-e4-b8-ba-e5-85-a8-e7-90-83-e4-b8-9a-e5-8a-a1-e6-8b-93-e5-b1-95-e8-b4-9f-e8-b4-a3-e4-ba-ba.html) (103 words)
- [Insilico Medicine Integrates Nach01 Foundation Model with Microsoft Discovery to Enable AI-Native, Enterprise-Ready Drug Discovery Workflows](/content/news/insilico-medicine-integrates-nach01-foundation-model-with-microsoft-discovery.html) (886 words)
- [Insilico Medicine Nominates ISM6200, a Potential Best-in-class Selective NR3C1 Inhibitor for Ovarian cancer, Cushing’s Syndrome, Hypercortisolism-associated obesity and Glaucoma](/content/news/zvgyb6jo11-insilico-medicine-nominates-ism6200-a-po.html) (909 words)
- [Insilico Announces Nature Medicine Publication of Phase IIa Results of Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis Discovered and Designed with a Pioneering AI Approach](/content/news/tnrecuxsc1-insilico-announces-nature-medicine-publi.html) (1,249 words)
- [Insilico Medicine and Taigen achieves license agreement to develop and commercialize AI-driven PHD inhibitor for anemia of Chronic Kidney Disease (CKD)](/content/news/bei1suokn1-insilico-medicine-and-taigen-achieves-li.html) (798 words)
- [AACR 2023 | Insilico Medicine](/content/events/aacr2023/index.html): Meet us there (442 words)
- [JMC Publication: Insilico’s AI platforms enable discovery of potent, selective, oral DGKα inhibitor to overcome checkpoint resistance](/content/news/392rraug51-jmc-publication-insilicos-ai-platforms-e.html) (1,005 words)
- [Security & IT | Insilico Medicine](/content/security/index.html): Our Commitment to Security (240 words)
- [Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies](/content/news/ckvxca1tu1-insilico-medicine-and-qilu-pharmaceutica.html) (768 words)
- [JMC Publication: Insilico’s Chemistry42 empowered efficient discovery of potent, oral CBLB inhibitor for immuno-oncology](/content/news/x0d9vcsxs1-jmc-publication-insilicos-chemistry42-em.html) (679 words)
- [Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase IIa Trial for Garutadustat, the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease](/content/news/gyjl5gbtd1-insilico-medicine-completes-first-patien.html) (609 words)
- [Insilico Medicine and Bora Pharmaceuticals Announce Strategic Alliance for AI-Driven Drug Discovery and Development](/content/news/xa31uheux1-insilico-medicine-and-bora-pharmaceutica.html) (920 words)
- [Liquid AI and Insilico Medicine Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery](/content/news/bo54fkt0e1-liquid-ai-and-insilico-medicine-announce.html) (706 words)
- [ir/media/0u3brrsi/insilico-dissemination-of-corporate-communications-final-c-pdf.html](/content/ir/media/0u3brrsi/insilico-dissemination-of-corporate-communications-final-c-pdf.html) (138 words)
- [404 | Insilico Medicine](/content/news_sc/k2oc6yjky1-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e6-88-90-e7-ab-8b-e4-b8-9a-e7-95-8c-e9-a6-96-e4-b8-aa-e9-95-bf-e5-af-bf-e5-a7-94-e5-91-98-e4-bc-9a-ef-bc-8c-e7-a4-bc-e6-9d-a5-e5-88-86-e5-ad-90-e5-8f-91-e7-8e-b0-e9-9b-86-e5-9b-a2-e5-89-af-e6-80-bb-e8-a3-81-e4-bb-bb-e4-b8-bb-e5-b8-ad.html) (103 words)
- [AI创新切入千亿市场：英矽智能提名AI驱动的临床前候选化合物ISM9528用于疼痛管理](/content/news_sc/jflyzzkc21-aiaiism9528/index.html) (71 words)
- [ir/media/oj3lliky/c_03696ann-20251229-20251229_0000-pdf.html](/content/ir/media/oj3lliky/c_03696ann-20251229-20251229_0000-pdf.html) (94 words)
- [直击AACR 2026｜英矽智能携四项AI发现临床前研究成果亮相](/content/news_sc/pk77ogvub1-aacr-2026ai/index.html) (350 words)
- [BIO 2026圆满收官｜英矽智能达成25亿美元重磅合作，持续引领AI制药创新](/content/news_sc/vnfvjca231-bio-202625ai/index.html) (75 words)
- [Pharma.AI 2026 年第二季度夏季网络研讨会：深入解读英矽智能最新平台升级](/content/news_sc/8x31ezxe91-pharmaai-2026/index.html) (211 words)
- [404 | Insilico Medicine](/content/news_sc/9v3s9l81t1-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e5-ae-a3-e5-b8-83-e4-b8-8e-e7-a4-bc-e6-9d-a5-e8-be-be-e6-88-90-e5-af-b9-e5-a4-96-e6-8e-88-e6-9d-83-e4-b8-8e-e5-85-a8-e7-90-83-e7-a0-94-e5-8f-91-e5-90-88-e4-bd-9c.html) (103 words)
- [ir/media/zfbk4q40/c_03696ann-20251228-20251228_2354-pdf.html](/content/ir/media/zfbk4q40/c_03696ann-20251228-20251228_2354-pdf.html) (59 words)
- [生成式AI出海：英矽智能提名阿联酋首款临床前候选药物](/content/news_sc/4dprm2i0j1-ai/index.html) (44 words)
- [404 | Insilico Medicine](/content/dora_sc/index.html) (121 words)
- [404 | Insilico Medicine](/content/precious_sc/index.html) (121 words)
- [404 | Insilico Medicine](/content/news/null/index.html) (103 words)
- [404 | Insilico Medicine](/content/nach01_sc/index.html) (113 words)
- [404 | Insilico Medicine](/content/inclinico_sc/index.html) (111 words)
- [404 | Insilico Medicine](/content/page15680537-html.html) (114 words)
- [404 | Insilico Medicine](/content/news_cn/index.html) (102 words)
- [ir/media/ehepcddm/c_ham25121057ann-20251229-20251229_1449-pdf.html](/content/ir/media/ehepcddm/c_ham25121057ann-20251229-20251229_1449-pdf.html) (919 words)
- [404 | Insilico Medicine](/content/generativebiologics_sc/index.html) (114 words)
- [英矽智能召开Rentosertib用于治疗IPF的III期临床试验研究者会议](/content/news_sc/m1x32po9f1-rentosertibipfiii/index.html) (54 words)
- [404 | Insilico Medicine](/content/chemistry42_sc/index.html) (116 words)
- [ir/media/fjwn1dej/c_ham25121671ann-20251229-20251229_0030-pdf.html](/content/ir/media/fjwn1dej/c_ham25121671ann-20251229-20251229_0030-pdf.html) (67 words)
- [ir/media/vk2c20oe/2025-annual-report-20260428-cn-pdf.html](/content/ir/media/vk2c20oe/2025-annual-report-20260428-cn-pdf.html) (6,628 words)
- [WAIC 2026｜AI+量子切入百亿美元体内CAR-T市场：英矽智能参投元码智药，并携手沙丘量子达成三方合作](/content/news_sc/el6xja8771-waic-2026aicar-t/index.html) (68 words)
- [404 | Insilico Medicine](/content/careers_cn/index.html) (114 words)
- [404 | Insilico Medicine](/content/dora_tc/index.html) (127 words)
- [404 | Insilico Medicine](/content/chemistry42_tc/index.html) (103 words)
- [英矽智能与衡泰生物的合作达成首个临床里程碑，AI 驱动的 NLRP3 抑制剂 ISM8969 完成 I 期临床试验首例受试者给药](/content/news_sc/9mgruc2gs1-ai-nlrp3-ism8969-i/index.html) (116 words)
- [英矽智能与奕拓医药深化战略合作，AI+液-液相分离加速皮肤抗衰千亿赛道药物创新](/content/news_sc/sccz2lvmo1-ai/index.html) (28 words)
- [英矽智能与武田制药达成超6亿美元战略合作，以生成式AI赋能多领域药物发现](/content/news_sc/a48o6xxvv1-6ai/index.html) (19 words)
- [404 | Insilico Medicine](/content/pandaomics_cn/index.html) (114 words)
- [AI驱动加速研发合作持续深入：英矽智能与康哲药业宣布在中枢神经系统疾病领域达成新合作](/content/news_sc/mb96iffd41-ai/index.html) (15 words)
- [404 | Insilico Medicine](/content/pandaomics_tc/index.html) (113 words)
- [404 | Insilico Medicine](/content/precious_tc/index.html) (114 words)
- [英矽智能与SK生物制药公司达成25亿美元AI药物研发合作， 聚焦神经免疫疾病领域](/content/news_sc/leod2xp2d1-sk25ai/index.html) (68 words)
- [404 | Insilico Medicine](/content/generativebiologics_tc/index.html) (121 words)
- [404 | Insilico Medicine](/content/contact_cn/index.html) (102 words)
- [404 | Insilico Medicine](/content/main_cn/index.html) (104 words)
- [英矽智能首款AI药物进入III期临床研究](/content/news_sc/1udp32slr1-aiiii/index.html) (58 words)
- [404 | Insilico Medicine](/content/nach01_tc/index.html) (103 words)
- [404 | Insilico Medicine](/content/about_cn/index.html) (114 words)
- [ir/media/hoopc0b3/c_ham25121426ann-20251228-20251228_2337-pdf.html](/content/ir/media/hoopc0b3/c_ham25121426ann-20251228-20251228_2337-pdf.html) (31 words)
- [404 | Insilico Medicine](/content/chemistry42_cn/index.html) (114 words)
- [404 | Insilico Medicine](/content/inclinico_tc/index.html) (126 words)
- [英矽智能将在 2026 年 BIO 国际大会上展示人工智能驱动的创新成果](/content/news_sc/gfejutds41-2026-bio/index.html) (139 words)
- [英矽智能与腾讯健康达成战略合作：共建生命科学AI专精模型，探索新药研发新边界](/content/news_sc/hb5gyoa9r1-ai/index.html) (21 words)
- [404 | Insilico Medicine](/content/publications_cn/index.html) (108 words)
- [NRDD | 影响因子129.8，英矽智能发布AI驱动的靶点发现与评估最新综述](/content/news_sc/i7mm700xl1-nrdd-1298ai/index.html) (36 words)
- [英矽智能与Human Longevity达成合作，共同开发业内首个面向长寿科学的 AI 基础模型](/content/news_sc/06oz2mpoe1-human-longevity-ai/index.html) (60 words)
- [Pharma.AI webinar 2026｜英矽智能Pharma.AI 春季更新解读](/content/news_sc/nfh73k4lk1-pharmaai-webinar-2026pharmaai/index.html) (188 words)
- [ir/media/ejljoxxx/insilico-medicine-list-of-directors-and-their-role-and-function-cn-pdf.html](/content/ir/media/ejljoxxx/insilico-medicine-list-of-directors-and-their-role-and-function-cn-pdf.html) (59 words)
- [首款“AI药物”融合制剂创新，英矽智能Rentosertib吸入制剂获临床试验批件](/content/news_sc/gsymxvni61-airentosertib/index.html) (70 words)
- [英矽智能提名潜在“同类最佳”NR3C1选择性拮抗剂ISM6200](/content/news_sc/tdlh6z0ea1-nr3c1ism6200/index.html) (32 words)
- [AACR 2026｜英矽智能四项临床前研究成果入选](/content/news_sc/r9tubl8h61-aacr-2026/index.html) (62 words)
- [Pharma.AI 2026春季发布会：驱动制药超级智能未来](/content/news_sc/ccr05dnou1-pharmaai-2026/index.html) (41 words)
- [Pharma.AI 2026 夏季发布会:驱动制药超级智能未来](/content/news_sc/gj31ro5gu1-pharmaai-2026/index.html) (118 words)
- [Scientific Reports | 英矽智能发布靶点识别新框架，推进 AI 驱动的早期药物发现](/content/news_sc/cypin7nlt1-scientific-reports-ai/index.html) (106 words)
- [Nominating Novel USP1 Small Molecule Inhibitor as a Preclinical Candidate for BRCA mutant tumors| Insilico Medicine](/content/usp1/index.html) (2,002 words)
- [投资者关系联络与邮件订阅 | 英矽智能](/content/ir/cn/contact-lr-and-email-alert/index.html) (246 words)
- [公司治理 | 英矽智能](/content/ir/hk/corporate-governance/index.html) (107 words)
- [英矽智能发布 PandaClaw：以智能体AI赋能生物学家开展治疗性发现](/content/news_sc/46ksi7o5h1-pandaclawai/index.html) (63 words)
- [Generative AI Leap: Insilico Medicine Nominates First Preclinical Candidate in the UAE](/content/news/yxenmllx01-generative-ai-leap-insilico-medicine-nom.html) (1,973 words)
- [Fast Company｜名列Top3，英矽智能入选《快公司》最具创新力公司榜单](/content/news_sc/1iyi9jg2u1-fast-companytop3/index.html) (25 words)
- [英矽智能提名ISM6166为泛KRAS临床前候选化合物，实现显著临床前肿瘤消退](/content/news_sc/ri5xdbjnr1-ism6166kras/index.html) (18 words)
- [投資者關係聯絡與郵件訂閱 | 英矽智能](/content/ir/hk/contact-lr-and-email-alert/index.html) (298 words)
- [英矽智能与太景合作达成里程碑，CKD贫血新药完成一期临床首例入组并给药](/content/news_sc/4ljnnoy9r1-ckd/index.html) (10 words)
- [英矽智能与元羿生物扩大 AI 驱动的 CNS 领域合作，合作总交易金额最高达 9475 万美元](/content/news_sc/yxettojt81-ai-cns-9475/index.html) (42 words)
- [ACS Central Science | 从提示词到药物，迈向制药超级智能的闭环研发愿景](/content/news_sc/h2yihz6db1-acs-central-science/index.html) (40 words)
- [MMAI Gym首个合作落地，英矽智能与Liquid AI发布轻量科研基础模型](/content/news_sc/xjk94yelj1-mmai-gymliquid-ai/index.html) (66 words)
- [Pipeline | Insilico Medicine](/content/pipeline/index.html) (284 words)
- [WHX 2026｜英矽智能宣布与阿联酋药品管理局（EDE）达成战略合作意向](/content/news_sc/tnbxv4hck1-whx-2026ede/index.html) (32 words)
- [英矽智能与ASKA制药达成战略合作，共同开展女性健康创新靶点发现](/content/news_sc/hakh1kil01-aska/index.html) (32 words)
- [Media Kit | Insilico Medicine](/content/mediakit/index.html) (854 words)
- [Agrochemistry](/content/interactive/agrochemistry/index.html) (553 words)
- [英矽智能将于2026年3月30日公布2025年度业绩](/content/news_sc/y2boj7aim1-20263302025/index.html) (27 words)
- [Case Study: Insilico's Transformation](/content/casestudy/index.html) (621 words)
- [投资者关系 | 英矽智能](/content/ir/cn/index.html) (86 words)
- [公告与通函 | 英矽智能](/content/ir/cn/information-disclosure/announcements-and-circulars/index.html) (34 words)
- [ENPP1 | Insilico Medicine](/content/pipeline_target_enpp1/index.html) (643 words)
- [Nature Communications: Insilico Medicine presents AI-empowered dual-action PROTAC targeting PKMYT1](/content/news/4oayh02je1-nature-communications-insilico-medicine/index.html) (1,088 words)
- [ESG | 英矽智能](/content/ir/cn/esg/index.html) (21 words)
- [Announcements & Circulars | Insilico Medicine](/content/ir/en/information-disclosure/announcements-and-circulars/index.html) (596 words)
- [投資者關係 | 英矽智能](/content/ir/hk/index.html) (50 words)
- [Contact lR & Email Alert | Insilico Medicine](/content/ir/en/contact-lr-and-email-alert/index.html) (565 words)
- [FGFR2/3 | Insilico Medicine](/content/pipeline_target_fgfr2/3/index.html) (435 words)
- [MAT2A | Insilico Medicine](/content/pipeline_target_mat2a/index.html) (509 words)
- [Pipeline | Insilico Medicine](/content/pipeline_fr/index.html) (373 words)
- [网络直播与演示文稿 | 英矽智能](/content/ir/cn/webcasts-and-presentations/index.html) (5 words)
- [Leveraging Chemistry42, Insilico nominates ISM3830 as preclinical candidate targeting CBLB for advanced tumors immunotherapy](/content/news/h0ftslh6s1-leveraging-chemistry42-insilico-nominate.html) (878 words)
- [ 上市文件 | 英矽智能](/content/ir/cn/information-disclosure/listing-documents/index.html) (4 words)
- [Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment](/content/news/r6iax95rk1-insilico-medicine-and-hygtia-therapeutic.html) (690 words)
- [公告與通函 | 英矽智能](/content/ir/hk/information-disclosure/announcements-and-circulars/index.html) (37 words)
- [Insilico Medicine, Mabwell Bioscience, and ChemExpress forging ahead with ADC innovation through strategic collaboration](/content/news/fjsry097r1-insilico-medicine-mabwell-bioscience-and.html) (732 words)
- [ESG | 英矽智能](/content/ir/hk/esg/index.html) (16 words)
- [AI赋能高效研发：英矽智能携手海正药业，8个月完成临床前候选化合物提名](/content/news_sc/hg3oco8n31-ai8/index.html) (7 words)
- [ESG | Insilico Medicine](/content/ir/en/esg/index.html) (158 words)
- [AI-Powered R&D Acceleration: Insilico Medicine and Hisun Pharma Nominate a Preclinical Candidate Just 8 Months After Forming a Strategic Collaboration](/content/news/xsn0l828t1-ai-powered-rampd-acceleration-insilico-m.html) (673 words)
- [網絡直播與演示文稿 | 英矽智能](/content/ir/hk/webcasts-and-presentations/index.html) (5 words)
- [ 上市文件 | 英矽智能](/content/ir/hk/information-disclosure/listing-documents/index.html) (4 words)
- [Webcasts & Presentations | Insilico Medicine](/content/ir/en/webcasts-and-presentations/index.html) (15 words)
- [Authentication required](/content/ir/corporate-governance_cn/tproduct/660972498-959772730781-3-board-diversity-policy/index.html) (1 words)
- [End User Terms and Conditions](/content/mmai/terms/index.html) (7,267 words)
- [英矽智能扩展 MMAI Gym，推出面向科学研究与药物发现的基准排行榜门户](/content/news_sc/9pyig80001-mmai-gym/index.html) (53 words)
- [404 | Insilico Medicine](/content/news_sc/c08hbr0vn1-e8-81-9a-e7-84-a6-e5-87-8f-e8-82-a5-e3-80-81-e4-bb-a3-e8-b0-a2-e3-80-81-e5-85-8d-e7-96-ab-e7-ad-89-e7-96-be-e7-97-85-e9-a2-86-e5-9f-9f-ef-bc-8c-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e8-90-bd-e5-ad-90-e5-ae-9c-e5-85-b4-e6-89-93-e9-80-a0-e5-8f-a3-e6-9c-8d-e5-a4-9a-e8-82-bd-e7-ad-9b-e9-80-89-e5-b9-b3-e5-8f-b0.html) (103 words)
- [End User Terms and Conditions | Science42:DORA](/content/science42/dora/terms/index.html) (5,112 words)
- [404 | Insilico Medicine](/content/news_sc/7hip0ffdb1-e8-8b-b1-e7-9f-bd-e6-99-ba-e8-83-bd-e4-b8-8e-e8-bf-88-e5-a8-81-e7-94-9f-e7-89-a9-e3-80-81-e7-9a-93-e5-85-83-e5-8c-bb-e8-8d-af-e8-be-be-e6-88-90-e6-88-98-e7-95-a5-e5-90-88-e4-bd-9c-e5-8d-8f-e8-ae-ae.html) (114 words)
- [End-to-End AI-Driven Design of a First-in-Class PKMYT1 PROTAC Using Chemistry42](/content/blog/pkmyt1-protac/index.html): This white paper focuses on the application of Chemistry42 for PROTAC design. (3,143 words)
- [404 | Insilico Medicine](/content/pandaomics_sc/index.html) (95 words)
- [CCC 2026｜三篇摘要入选，英矽智能将分享ISM5411安全性和有效性数据](/content/news_sc/czmcnyp661-ccc-2026ism5411/index.html) (55 words)
- [Privacy Policy](/content/generativebiologics/privacy/index.html) (3,179 words)
- [ir/media/gx5fm2ge/c_03696ann-20251229-20251229_0012-pdf.html](/content/ir/media/gx5fm2ge/c_03696ann-20251229-20251229_0012-pdf.html) (99 words)
- [Insilico Medicine Showcases Preclinical Breakthroughs for Four AI-Powered Oncology Pipelines at AACR Annual Meeting 2026](/content/news/z21rzi2mv1-insilico-medicine-showcases-preclinical/index.html) (1,869 words)
- [Financial Reports | Insilico Medicine](/content/ir/en/information-disclosure/financial-reports/index.html) (5 words)
- [Insilico Pharma.AI fall launch recap: Understand latest AI updates for healthcare research with frequent questions answered](/content/news/003kiu5pv1-insilico-pharmaai-fall-launch-recap-unde.html) (2,714 words)
- [Privacy Policy | Science42:DORA](/content/science42/dora/privacy/index.html) (3,473 words)
- [Privacy Policy](/content/mmai/privacy/index.html) (3,472 words)
- [Privacy Policy](/content/inclinico/privacy/index.html) (3,364 words)
- [Pharma.AI 2025 年第四季度冬季发布回顾：前沿 AI 创新重塑药物发现](/content/news_sc/y5y7ir0bt1-pharmaai-2025-ai/index.html) (202 words)
- [Privacy Policy](/content/privacy/index.html) (3,242 words)
- [英矽智能首发AI业务拓展平台，加速管线资产与AI平台授权](/content/news_sc/nsex99bn21-aiai/index.html) (61 words)
- [英矽智能与齐鲁制药达成总额9.31亿港元药物研发合作， 加速心血管与代谢类疾病创新疗法](/content/news_sc/lnhaeoho31-931/index.html) (18 words)
- [英矽智能携手沙特阿美，发布AI筛选与验证“流水线”Sanity Pipeline](/content/news_sc/9p4t49gie1-aisanity-pipeline/index.html) (32 words)
- [英矽智能任命Halle Zhang博士为肿瘤项目临床开发副总裁](/content/news_sc/0hhgd2r9i1-halle-zhang/index.html) (39 words)
- [英矽智能提名CBLB抑制剂ISM3830，用于晚期肿瘤免疫治疗](/content/news_sc/3m4rps1kk1-cblbism3830/index.html) (86 words)
- [减重高达31.3%！英矽智能提名AI赋能的GIPR拮抗剂ISM0676为临床前候选化合物，与司美格鲁肽联用展现强劲协同减重效果](/content/news_sc/9v1dmeuro1-313aigiprism0676/index.html) (22 words)
- [英矽智能获 Microsoft Azure 支持开源 DORA，以多智能体大模型重塑科学研究与内容创作](/content/news_sc/4o36s9mhj1-microsoft-azure-dora/index.html) (98 words)
- [英矽智能提名外周限制性NLRP3抑制剂ISM5059为临床前候选化合物](/content/news_sc/kun1c7szf1-nlrp3ism5059/index.html) (25 words)
- [衰老 | 英矽智能利用人工智能工具揭示特发性肺纤维化与加速衰老的关联](/content/news_sc/kt0yfl6er1/index.html) (49 words)
- [英矽智能上线大语言模型训练框架MMAI Science Gym](/content/news_sc/18j75fduj1-mmai-science-gym/index.html) (105 words)
- [财务报告 | 英矽智能](/content/ir/cn/information-disclosure/financial-reports/index.html) (2 words)
- [Pharma.AI Q2 2026 Summer Webinar: A Deep Dive into Insilico Medicine’s Latest Platform Upgrades](/content/news/er6gnm3741-pharmaai-q2-2026-summer-webinar-a-deep-d.html) (1,136 words)
- [英矽智能于IIa期临床试验BETHESDA完成首例患者给药](/content/news_sc/v13a3v9fm1-iiabethesda/index.html) (37 words)
- [Springer Nature｜英矽智能药研实践登上AI制药前沿应用指南](/content/news_sc/rx9i1z0hl1-springer-natureai/index.html) (79 words)
- [Advancing Drug Discovery from Automation to Autonomy: Insilico Medicine Announces LabClaw the Intelligent System](/content/news/tmikccj2f1-advancing-drug-discovery-from-automation.html) (1,263 words)
- [JPM 2026｜英矽智能Nach01多模态基础模型入驻微软Discovery](/content/news_sc/cjb0cf7en1-jpm-2026nach01discovery/index.html) (23 words)
- [英矽智能携手纪念斯隆-凯特琳癌症中心，探索胃食管癌潜在新颖治疗靶点](/content/news_sc/x20gfu3h61/index.html) (59 words)
- [英矽智能今日挂牌港交所，AI制药引领年内最大港股Biotech IPO](/content/news_sc/yv1sumnn21-aibiotech-ipo/index.html) (34 words)
- [AI驱动研发加速：英矽智能与康哲药业宣布在中枢神经系统及自身免疫疾病领域达成多项合作](/content/news_sc/ft5l5r83a1-ai/index.html) (13 words)
- [英矽智能潜在同类最佳NLRP3抑制剂ISM8969获FDA临床试验批件](/content/news_sc/labcvtssp1-nlrp3ism8969fda/index.html) (15 words)
- [英矽智能NLRP3抑制剂ISM8969完成IND-enabling研究，用于帕金森病治疗](/content/news_sc/3l0jgfc7k1-nlrp3ism8969ind-enabling/index.html) (31 words)
- [英矽智能与太景达成管线授权合作，加速ISM4808开发和商业化](/content/news_sc/kgblly8jv1-ism4808/index.html) (28 words)
- [团队 | Insilico Medicine](/content/team_sc/index.html) (214 words)
- [Insilico Medicine’s Pharma.AI Q4 Winter Launch Recap: Revolutionizing drug discovery with cutting-edge AI innovations, accelerating the path to pharmaceutical superintelligence](/content/news/rl3orlsn41-insilico-medicines-pharmaai-q4-winter-la.html) (1,133 words)
- [英矽智能获美纳里尼3900万港币里程碑付款，合作项目MEN2501完成首例患者给药](/content/news_sc/pl99nj1o51-3900men2501/index.html) (19 words)
- [哈佛商学院案例分析｜走近英矽智能Rentosertib研发历程](/content/news_sc/dt2e5ogh61-rentosertib/index.html) (25 words)
- [Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders](/content/news/zm8me18st1-insilico-medicine-and-sk-biopharmaceutic.html) (836 words)
- [英矽智能亮相 WHX 2026：连接中东与全球合作伙伴，推动转化研究落地](/content/news_sc/7xbbyxymi1-whx-2026/index.html) (51 words)
- [逾5亿港币合作，英矽智能与衡泰生物共同开发创新透脑性NLRP3抑制剂](/content/news_sc/ood0862nd1-5nlrp3/index.html) (56 words)
- [chemistry42/end_user_terms/index.html](/content/chemistry42/end_user_terms/index.html) (19 words)
- [PHD1/2 | Insilico Medicine](/content/pipeline/phd1/2_sc/index.html) (294 words)
- [Insilico Medicine and Human Longevity Announce Collaboration to Co-Develop Industry-First AI Foundation Model for Longevity Science](/content/news/ps2bndbh61-insilico-medicine-and-human-longevity-an.html) (759 words)
- [Alex Zhavoronkov博士再次蝉联全球前1%高被引科学家](/content/news_sc/hrrbxs6fe1-alex-zhavoronkov1/index.html) (19 words)
- [英矽智能宣布与施维雅达成价值 8.88 亿美元的抗肿瘤药物研发合作](/content/news_sc/8s0t6ly461-888/index.html) (32 words)
- [Pharma.AI Webinar 2026 | Deciphering the Spring Kickoff Updates from Insilico Medicine](/content/news/76497ubnc1-pharmaai-webinar-2026-deciphering-the-sp.html) (863 words)
- [Insilico Medicine caps monumental week at BIO 2026: Secures landmark $2.5B partnership and dominates thought leadership](/content/news/tt2t6rbzr1-insilico-medicine-caps-monumental-week-a.html) (682 words)
- [公司治理 | 英矽智能](/content/ir/cn/corporate-governance/index.html) (110 words)
- [Pharma.AI Summer Update Preview: Drive the future of pharmaceutical intelligence](/content/news/fzshrjdhj1-pharmaai-summer-update-preview-drive-the.html) (793 words)
- [英矽智能与礼来达成AI驱动药物研发合作，总额逾亿美元](/content/news_sc/et5l2dr0a1-ai/index.html) (7 words)
- [TNIK | Insilico Medicine](/content/pipeline/tnik_sc/index.html): TNIK 抑制剂：治疗肺部和肾脏纤维化疾病( IIa 期临床已完成) (368 words)
- [Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics](/content/news/bno2kl4lp1-insilico-completes-first-in-human-dosing.html) (742 words)
- [聚焦“合成致死”策略，英矽智能发现靶向USP1的临床前候选药物，用于多种抗肿瘤疗法开发| Insilico Medicine](/content/usp1cn/index.html): 聚焦“合成致死”策略，英矽智能发现靶向USP1的临床前候选药物，用于多种抗肿瘤疗法开发 (93 words)
- [Insilico Medicine’s CEO Dr. Alex Zhavoronkov recognized among global top one per cent for pharmacology and toxicology](/content/news/szj9574dv1-insilico-medicines-ceo-dr-alex-zhavoronk.html) (789 words)
- [TR50｜英矽智能再登《麻省理工科技评论》“50家聪明公司”年度榜单](/content/news_sc/h1jd0ge311-tr5050/index.html) (26 words)
- [Pharma.AI Spring Kickoff 2026: Drive the Future of Pharmaceutical Intelligence](/content/news/bnj09h4811-pharmaai-spring-kickoff-2026-drive-the-f.html) (881 words)
- [Insilico’s Rentosertib Inhalation Solution Receives IND Clearance for the World’s First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study](/content/news/pdmncgky51-insilicos-rentosertib-inhalation-solutio.html) (942 words)
- [PCC CN | Insilico Medicine](/content/blog_cn/pcc/index.html) (115 words)
- [Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases](/content/news/2fx6em2jc1-deepening-collaboration-in-ai-powered-ra.html) (522 words)
- [Insilico Medicine and Saudi Aramco Introduce the “Sanity Pipeline” to Advance AI-driven Discovery of MOFs](/content/news/f8il5i2j91-insilico-medicine-and-saudi-aramco-intro.html) (623 words)
- [Insilico Pilots the Automated AI-driven Partnering System for Biotechnology Assets and AI Platforms](/content/news/75jecr6kc1-insilico-pilots-the-automated-ai-driven/index.html) (1,321 words)
- [Insilico Medicine Appoints Jue Wang, PhD as Global Head of Business Development](/content/news/s8o11au3t1-insilico-medicine-appoints-jue-wang-phd/index.html) (507 words)
- [404 | Insilico Medicine](/content/platform_cn/index.html) (114 words)
- [PCC | Insilico Medicine](/content/blog/pcc/index.html) (3,746 words)
- [Insilico Medicine Advances AI-Driven Target Discovery with Validated TargetPro–TargetBench Framework](/content/news/77g216v1e1-insilico-medicine-advances-ai-driven-tar.html) (650 words)
- [Insilico Medicine Featured in Harvard Business School Case on Rentosertib](/content/news/8tx5ducrx1-insilico-medicine-featured-in-harvard-bu.html) (648 words)
- [Insilico Medicine to Announce 2025 Financial Results on March 30, 2026](/content/news/5a9ntf64a1-insilico-medicine-to-announce-2025-finan.html) (287 words)
- [Meet us at BIO-Europe | Insilico to showcase generative AI platform and introduce cardiometabolic portfolio at BIO-Europe 2025 in Vienna](/content/news/x7nnvdlkl1-meet-us-at-bio-europe-insilico-to-showca.html) (537 words)
- [FIH | Insilico Medicine](/content/blog/fih/index.html): Insilico Medicine Initiates First-in-Human Study of ISM001-055,a Novel Drug Discovered Using Insilico’s ProprietaryEnd-to-end Artificial Intelligence Platform (3,153 words)
- [ACS Central Science | Researchers from Insilico Medicine and Lilly publish foundational vision for fully autonomous “Prompt-to-Drug” pharmaceutical R&D](/content/news/ab20uoke81-acs-central-science-researchers-from-ins.html) (835 words)
- [chemistry42/corporate_terms/index.html](/content/chemistry42/corporate_terms/index.html) (19 words)
- [Insilico Open-sources DORA on GitHub, supported by Microsoft Azure, Transforming Scientific Research and Content Creation with Multi-Agent LLMs](/content/news/kv5e80yc41-insilico-open-sources-dora-on-github-sup.html) (755 words)
- [chemistry42/privacy/index.html](/content/chemistry42/privacy/index.html) (20 words)
- [Insilico Medicine Announces Industry’s First Longevity Board to Accelerate AI-Driven Aging Research for Drug Discovery](/content/news/vxuidy8ph1-insilico-medicine-announces-industrys-fi.html) (742 words)
- [Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate](/content/news/akink88ao1-insilico-medicine-nominates-ism5059-the/index.html) (626 words)
- [首页 | Insilico Medicine](/content/main_sc/index.html): Generative AI and Robotics for Longevity and Sustainability (123 words)
- [QPCTL | Insilico Medicine](/content/pipeline/qpctl_sc/index.html) (141 words)
- [Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines](/content/news/l16526c8p1-insilico-medicine-launches-science-mmai/index.html) (714 words)
- [TEAD | Insilico Medicine](/content/pipeline/tead_sc/index.html) (153 words)
- [USP1 | Insilico Medicine](/content/pipeline/usp1_sc/index.html): 泛素特异性蛋白酶 1 (USP1) 抑制剂： 治疗 BRCA 突变癌症 (195 words)
- [Insilico Medicine Initiates AI-Driven Collaboration with Leading Global Cancer Center to Identify Novel Targets for Gastroesophageal Cancers](/content/news/ncd16c90n1-insilico-medicine-initiates-ai-driven-co.html) (557 words)
- [Join Insilico Medicine at NeurIPS 2025: Unveiling generative AI breakthroughs revolutionizing drug discovery and development](/content/news/d9b89i8s81-join-insilico-medicine-at-neurips-2025-u.html) (589 words)
- [AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases](/content/news/j2ajn0e5y1-ai-powered-rampd-acceleration-insilico-m.html) (803 words)
- [MAT2A | Insilico Medicine](/content/pipeline/mat2a_sc/index.html) (143 words)
- [Insilico Medicine Nominates Pan-KRAS Preclinical Candidate ISM6166 to Tackle “Undruggable” Solid Tumors, Showing Tumor Regression in Preclinical Studies](/content/news/voro4cfnv1-insilico-medicine-nominates-pan-kras-pre.html) (653 words)
- [Insilico Medicine Launches PandaClaw: Empowering Biologists with Agentic AI for Therapeutic Discovery](/content/news/spjz8fzmb1-insilico-medicine-launches-pandaclaw-emp.html) (594 words)
- [Automated data preparation for QSAR modeling](/content/blog/automated-data-for-qsar/index.html) (952 words)
- [Insilico Medicine and ASKA Pharmaceutical Expand Partnership to Discover Novel Targets for Women’s Health](/content/news/2fx40la551-insilico-medicine-and-aska-pharmaceutica.html) (579 words)
- [Insilico Medicine named to Fast Company’s annual list of the world’s most innovative companies of 2026](/content/news/yayygle7n1-insilico-medicine-named-to-fast-companys.html) (662 words)
- [404 | Insilico Medicine](/content/treatmentalscn/index.html) (114 words)
- [Insilico Medicine to Showcase at WHX 2026, Bridging Middle East–Global Partnerships to Accelerate Translational Research](/content/news/1dtymbokl1-insilico-medicine-to-showcase-at-whx-202.html) (491 words)
- [Insilico Medicine and Tenacia Biotechnology Expand AI-Driven CNS Collaboration with Deal Value Up to US$94.75 Million](/content/news/99t6vd21h1-insilico-medicine-and-tenacia-biotechnol.html) (598 words)
- [Insilico Medicine unveils winter edition of Pharma.AI, accelerating the path to pharmaceutical superintelligence](/content/news/2ky5zn0fs1-insilico-medicine-unveils-winter-edition.html) (747 words)
- [Transforming Drug Target Discovery, Insilico Medicine Publishes Landmark Paper Introducing AI-empowered Target Identification Pro (TargetPro) and TargetBench 1.0](/content/news/v49bfcu0r1-transforming-drug-target-discovery-insil.html) (970 words)
- [管线 | Insilico Medicine](/content/pipeline_sc/index.html): 基于PHARMA.AI发现 (83 words)
- [Insilico Medicine CEO Alex Zhavoronkov to speak on longevity and AI in healthcare at Fortune Global Forum in Riyadh](/content/news/8l3pdpvg21-insilico-medicine-ceo-alex-zhavoronkov-t.html) (634 words)
- [ARDD for healthy longevity: How science, technology and investment are redefining the future](/content/news/zxgcbd5dx1-ardd-for-healthy-longevity-how-science-t.html) (798 words)
- [Insilico showcases advanced generative biologics engine in breakthrough 72-hour peptide design targeting GLP1R for cardiometabolic disease](/content/news/o1y20pfyz1-insilico-showcases-advanced-generative-b.html) (748 words)
- [Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology](/content/news/u4cbsok2s1-insilico-medicine-announces-us888-millio.html) (621 words)
- [KAT6 | Insilico Medicine](/content/pipeline/kat6_sc/index.html) (134 words)
- [Insights to Innovation: Insilico Medicine AI-driven Practice Published on Springer Nature  in Latest AI for Drug Discovery Volume](/content/news/sucsgavup1-insights-to-innovation-insilico-medicine.html) (684 words)
- [Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor](/content/news/az7xmeem81-insilico-medicine-receives-ind-approval/index.html) (622 words)
- [Insilico Medicine Receives USD 5 Million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501](/content/news/g3l291v091-insilico-medicine-receives-usd-5-million.html) (588 words)
- [Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology](/content/news/kjrb3mu8l1-insilico-medicine-appoints-halle-zhang-p.html) (745 words)
- [ISM6166, pan-KRAS Poster](/content/ism6166_pan-kras_poster/index.html): ISM6166, a novel oral pan-KRAS (ON/OFF) inhibitor discovered with generative AI shows robust anti-tumor activity in solid tumors with KRAS alterations (25 words)
- [Insilico Medicine Announces Global R&D Collaboration with Lilly](/content/news/uiy12zcjg1-insilico-medicine-announces-global-rampd.html) (308 words)
- [ENPP1 | Insilico Medicine](/content/pipeline/enpp1_sc/index.html): 外核苷酸磷酸二酯酶 1 (ENPP1) 抑制剂：治疗抗 PD-1/-L1 耐药癌症 (170 words)
- [Insilico Medicine and Atossa Therapeutics publish AI-driven study in Nature's Scientific Reports identifying (Z)-endoxifen as a potential therapeutic candidate for glioblastoma](/content/news/a58sk08ak1-insilico-medicine-and-atossa-therapeutic.html) (709 words)
- [Insilico Medicine leadership to attend 44th Annual J.P. Morgan Healthcare Conference](/content/news/6pja1406r1-insilico-medicine-leadership-to-attend-4.html) (509 words)
- [Insilico Medicine named a 2025 BostInno Fire Awards honoree](/content/news/li8xtjc1a1-insilico-medicine-named-a-2025-bostinno/index.html) (407 words)
- [llms.txt — Insilico Medicine ](/content/llmstxt/index.html): How AI agents should use Insilico Medicine's content: structured company data via the Company MCP server, and the website pages description for everything else.  (525 words)
- [Teaching AI the Language of Molecules](/content/blog/mmai-liquid-ai/index.html): How MMAI Gym and Liquid Intelligence are Solving the “Brute Force” Crisis in Drug Discovery (998 words)
- [媒体资料包 | Insilico Medicine](/content/mediakit_sc/index.html) (159 words)
- [Meet us at PFF Summit 2025 | Insilico Medicine to showcase generative AI platform and introduce their latest AI-driven Pulmonary Fibrosis clinical research at PFF Summit 2025 in Chicago, IL](/content/news/ot1bbsv451-meet-us-at-pff-summit-2025-insilico-medi.html) (376 words)
- [Insilico employs AI-driven tools to uncover the link between idiopathic pulmonary fibrosis (IPF) and accelerated aging](/content/news/5t5cdcvdj1-insilico-employs-ai-driven-tools-to-unco.html) (515 words)
- [AI power for future growth: Insilico leadership team to speak at FII 2025](/content/news/t0azmxan51-ai-power-for-future-growth-insilico-lead.html) (369 words)
- [Pharma.ai summer 2025 updates: Join Insilico Medicine on July 10 for the future of AI-empowered medical research boost](/content/news/fhoex9ed01-pharmaai-summer-2025-updates-join-insili.html) (730 words)
- [Insilico at AACR: Four Innovative Posters Demonstrating the Power of Generative AI](/content/events/a82iia5on1-insilico-at-aacr-four-innovative-posters.html) (888 words)
- [On-demand recording and key takeaway available: Insilico introduces generative AI platform enhancements across drug discovery stages in Pharma.ai summer updates webinar](/content/news/es8y9gs211-on-demand-recording-and-key-takeaway-ava.html) (477 words)
- [Transforming Parkinson’s disease treatment, Insilico Medicine announces IND-enabling completion for AI-empowered oral NLRP3 inhibitor ISM8969](/content/news/fyvt4m40f1-transforming-parkinsons-disease-treatmen.html) (675 words)
- [Insilico ranked Top50 in USA in Nature Index’s “2025 Research Leaders: Global corporate institutions for all-subject output”](/content/news/97pt0u8m81-insilico-ranked-top50-in-usa-in-nature-i.html) (518 words)
- [Showcasing gen-AI breakthroughs, Insilico Medicine presents fall edition of Pharma.AI quarterly launch](/content/news/rd037pu8d1-showcasing-gen-ai-breakthroughs-insilico.html) (463 words)
- [Media Coverage | Insilico Medicine](/content/mediacoverage/index.html) (920 words)
- [MAT2A | Insilico Medicine](/content/pipeline_target_mat2a_fr/index.html) (588 words)
- [Observer AI Power Index: Alex Zhavoronkov, PhD, founder of Insilico Medicine acknowledged among 100 future-shaping leaders](/content/news/etp5tbcg91-observer-ai-power-index-alex-zhavoronkov.html) (332 words)
- [Insilico Medicine launches Nach01 Foundation model on AWS Marketplace to help accelerate generative chemistry innovation](/content/news/n4y7nk0f31-insilico-medicine-launches-nach01-founda.html) (519 words)
- [JMC | Insilico Medicine publishes AI-driven innovative design strategy for highly selective FGFR2/3 inhibitors](/content/news/hr2eyfocx1-jmc-insilico-medicine-publishes-ai-drive.html) (586 words)
- [可持续发展 | Insilico Medicine](/content/sustainability_sc/index.html): 生成式人工智能赋能 环境可持续性 联盟 (80 words)
- [Insilico and Lilly enter a research and licensing collaboration to advance AI-driven drug discovery](/content/news/e9xm9y0if1-insilico-and-lilly-enter-a-research-and/index.html) (275 words)
- [Équipe | Insilico Medicine](/content/team_fr/index.html) (2,068 words)
- [DGKA | Insilico Medicine](/content/pipeline_target_dgka_fr/index.html) (867 words)
- [Towards pharmaceutical super intelligence: During BioHK 2025, Insilico Medicine gathers industry leaders to shape the future of AI in healthcare](/content/news/405p809pv1-towards-pharmaceutical-super-intelligenc.html) (444 words)
- [PHD1/2 | Insilico Medicine](/content/pipeline_target_phd_fr/index.html) (1,109 words)
- [Science42: DORA| Blog | Insilico Medicine](/content/blog/science42-dora/index.html): Revealing the Draft Outline Research Assistant workflow (1,953 words)
- [Insilico Medicine to Showcase AI-Driven Innovation at BIO 2026 International Convention](/content/events/tuhn944aj1-insilico-medicine-to-showcase-ai-driven/index.html) (551 words)
- [AI for Good Global Summit: Dive into the future potential of generative AI with Alex Zhavoronkov PhD, Insilico’s founder and CEO](/content/news/xv599902a1-ai-for-good-global-summit-dive-into-the/index.html) (277 words)
- [Cookies Policy | Science42: DORA | Insilico Medicine](/content/science42/dora/cookies/index.html) (645 words)
- [生成式人工智能賦能 環境可持續性 聯盟 | Insilico Medicine](/content/sustainability_tc/index.html): 我們的使命是開發和推廣開源的前沿生成式AI技術，以促進環境可持續性。 (139 words)
- [ENPP1 | Insilico Medicine](/content/pipeline_target_enpp1_fr/index.html) (795 words)
- [Insilico Medicine to Showcase at WHX 2026, Bridging Middle East–Global Partnerships to Accelerate Translational Research](/content/events/ei3nsnc931-insilico-medicine-to-showcase-at-whx-202.html) (491 words)
- [FGFR2/3 | Insilico Medicine](/content/pipeline_target_fgfr2/3_fr/index.html) (553 words)
- [Cookies Policy](/content/cookies/index.html) (646 words)
- [Precious3GPT Data Repository | Insilico Medicine](/content/repository/precious3gpt/index.html) (737 words)
- [使命 | Insilico Medicine](/content/about_sc/index.html) (38 words)
- [Inhaled Rentosertib (INS018_055) Safety Tolerability ](/content/rentosertib-inhaled_safety-tolerability_poster/index.html): Inhaled Rentosertib (INS018_055), A Novel TNIK Inhibitor Discovered Using Generative AI, Exhibits High Safety and Tolerability in Animal Models (25 words)
- [TEAD | Insilico Medicine](/content/pipeline_target_tead_fr/index.html) (599 words)
- [联系方式 | Insilico Medicine](/content/contact_sc/index.html) (52 words)
- [USP1 | Insilico Medicine](/content/pipeline_target_usp1_fr/index.html) (783 words)
- [参会信息 | Insilico Medicine](/content/events_sc/index.html) (98 words)
- [ISM6260, CDK4 Poster](/content/ism6260_cdk4_poster/index.html): ISM6210, a potent and selective AI-discovered CDK4 inhibitor for the treatment of HR+/HER2- breast cancer (19 words)
- [Covering Patent Holes: How LEGION Uses AI to Block Competition in Chemical Space](/content/blog/legion/index.html) (1,989 words)
- [TNIK | Insilico Medicine](/content/pipeline_target_tnik_fr/index.html) (735 words)
- [ISM3830, CBLB Poster](/content/ism3830_cblb_poster/index.html): Cbl-b inhibition with ISM3830, a novel AI-generated small molecule, restores innate and adaptive immunity and demonstrates antitumor activity against solid tumors in vitro and in vivo (32 words)
- [ISM1745, PRMT5 Poster](/content/ism1745_prmt5_poster/index.html): ISM1745, an MTA-cooperative PRMT5 inhibitor discovered with generative AI for the treatment of MTAP-deleted cancer (19 words)
- [QPCTL | Insilico Medicine](/content/pipeline_target_qpctl_fr/index.html) (705 words)
- [人工智能预测的双重靶点| Insilico Medicine](/content/dual-purposetherapeutictargetspredictedusingaichina.html): 人工智能预测的双重靶点 (64 words)
- [新闻发布 | Insilico Medicine](/content/news_sc/index.html) (14 words)
- [Insilico Medicine: End-to-end generative AI-driven drug discovery and development](/content/insilico_ris2026_poster/index.html): RIS 2026 Featured Success Story (18 words)
- [KAT6 | Insilico Medicine](/content/pipeline_target_kat6_fr/index.html) (635 words)
- [Inhaled Rentosertib (INS018_055) Phase 1 Design](/content/rentosertib-inhaled_phase1-design_poster/index.html): Study Design of a Phase 1, Randomized, Double blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled Rentosertib (INS018_055), A Novel AI-Generated TNIK Inhibitor (33 words)
- [Inhaled Rentosertib (INS018_055) Lung exposure](/content/rentosertib-inhaled_lung-exposure_poster/index.html): Inhaled Rentosertib (INS018_055), a TNIK Inhibitor Discovered Using Generative AI, Achieves High And Specific Pulmonary Exposure In Healthy And Fibrotic Lungs (27 words)
- [PandaOmics | Insilico Medicine](/content/pandaomics_fr/index.html): Expand your horizons of data analysis and visualization (722 words)
- [PCC for Kidney Fibrosis | Insilico Medicine](/content/blog/pcc_kidney/index.html): Building on top of recent success in identifying a novel pan-fibrotic target and a promising preclinical candidate in Idiopathic Pulmonary Fibrosis (IPF) using AI-platform, Insilico Medicine reports a new milestone — an in vivo active molecule to tackle Kidney Fibrosis (KF) — a growing unmet medical need.  (2,157 words)
- [CDK12/13 | Insilico Medicine](/content/pipeline_target_cdk12/13_fr/index.html) (485 words)
- [Data Repository for TNIK | Insilico Medicine](/content/repository/nbt-ins018-055-tnik/index.html) (317 words)
- [利用英矽智能的人工智能平台，研究团队发现治疗ALS新希望 | Insilico Medicine](/content/treatmentals_cn/index.html): 利用英矽智能的人工智能平台，研究团队发现治疗ALS新希望 (60 words)
- [Insilico Medicine](/content/main_fr/index.html): INTELLIGENCE ARTIFICIELLE POUR CHAQUE ÉTAPE DE LA RECHERCHE ET DU DÉVELOPPEMENT PHARMACEUTIQUE (646 words)
- [DGKA | Insilico Medicine](/content/pipeline_target_dgka/index.html) (707 words)
- [Inhaled Rentosertib (INS018_055) Preclinical Efficacy Fibrosis](/content/rentosertib-inhaled_preclinical-efficacy-fibrosis_poster.html): Inhaled Rentosertib (ISM018_055), A Selective TNIK Inhibitor Generated By AI, Improves Lung Function and Reduces Fibrosis and Inflammation In Animal Models Of Pulmonary Fibrosis (28 words)
- [Insilico Medicine announces positive topline results of ISM001-055 for the treatment of idiopathic pulmonary fibrosis (IPF) developed using generative AI](/content/news/tnik-ipf-phase2a/index.html) (1,431 words)
- [Dual-purpose therapeutic targets predicted using AI| Insilico Medicine](/content/dual-purposetherapeutictargetspredictedusingai/index.html): Dual-purpose therapeutic targets predicted using AI (1,522 words)
- [加入我们 | Insilico Medicine](/content/careers_sc/index.html): Working at Insilico Medicine (6 words)
- [From Start to Phase 1 in 30 Months | Insilico Medicine](/content/phase1/index.html): From Start to Phase 1 in 30 Months: AI-discovered and AI-designed Anti-fibrotic Drug Enters Phase I Clinical Trial (1,877 words)
- [Pharma.ai](/content/platform_fr/index.html) (572 words)
- [PHD1/2 | Insilico Medicine](/content/pipeline/phd1/2_tc/index.html) (275 words)
- [3CLpro | Insilico Medicine](/content/pipeline_target_3clpro_fr/index.html) (525 words)
- [First Generative AI Drug Begins Phase II Trials with Patients | Insilico Medicine](/content/blog/first_phase2/index.html): New Milestone in AI Drug Discovery: First Generative AI Drug Begins Phase II Trials with Patients (1,238 words)
- [inClinico | Insilico Medicine](/content/inclinico_fr/index.html) (409 words)
- [BindHack: The Protein Affinity Hackathon | Insilico Medicine](/content/ism-events/abu-dhabi/hackathon2025/index.html): Participate in the AI-driven Dug Discovery Hackathon in Abu Dhabi organized by Insilico medicine (594 words)
- [Docuthon CN | Insilico Medicine](/content/docuthon_cn/index.html): Making history by cutting it (397 words)
- [Chemistry42 | Insilico Medicine](/content/chemistry42_fr/index.html): Harness the power of Generative AI and Physics-based methods (238 words)
- [PCC for Kidney Fibrosis | Insilico Medicine](/content/blog_cn/pcc_kidney/index.html): Building on top of recent success in identifying a novel pan-fibrotic target and a promising preclinical candidate in Idiopathic Pulmonary Fibrosis (IPF) using AI-platform, Insilico Medicine reports a new milestone — an in vivo active molecule to tackle Kidney Fibrosis (KF) — a growing unmet medical need.  (133 words)
- [KIF18A | Insilico Medicine](/content/pipeline_target_kif18a/index.html) (355 words)
- [Docuthon | Insilico Medicine](/content/docuthon/index.html): Making history by cutting it (575 words)
- [Drug Discovery Hackathon | Insilico Medicine](/content/ism-events/abu-dhabi/hackathon2024/index.html): Participate in the AI-driven Dug Discovery Hackathon in Abu Dhabi organized by Insilico medicine (587 words)
- [TEAD | Insilico Medicine](/content/pipeline_target_tead/index.html) (513 words)
- [BIO International Convention 2023 | Insilico Medicine](/content/events/bio-international2023/index.html): Meet us there (255 words)
- [AI for Longevity and Prosperity | Insilico Medicine](/content/blog/series_d_round/index.html): AI for Longevity and Prosperity: Prosperity7 Leads Insilico’s $35 Million Round D2 for $95 Million Total Raise (967 words)
- [A Phase 2 Readout Generates Excitement for the Potential of AI-Driven Drug Discovery](/content/blog/1112/index.html) (1,241 words)
- [Contactez-nous | Insilico Medicine](/content/contact_fr/index.html) (227 words)
- [QPCTL | Insilico Medicine](/content/pipeline_target_qpctl/index.html) (579 words)
- [KAT6 | Insilico Medicine](/content/pipeline_target_kat6/index.html) (531 words)
- [chemistry42/index.html](/content/chemistry42/index.html) (170 words)
- [ISM001-055 Phase2a Biomarker Poster](/content/ism001-055_phase2a_biomarker_poster/index.html): Antifibrotic And Anti-inflammatory Signatures In Idiopathic Pulmonary Fibrosis Patients Treated With Rentosertib (INS018_055), An AI-discovered TNIK Inhibitor, In A 12-week Phase 2a Study (30 words)
- [ISM001-055 Phase2a Efficacy Poster](/content/ism001-055_phase2a_efficacy_poster/index.html): Rentosertib (INS018_055), A Novel AI-Designed TNIK Inhibitor, Improves Lung Function In Patients With Idiopathic Pulmonary Fibrosis: Results From A Randomized, Placebo-controlled Phase 2a Study (31 words)
- [ISM5411, PHD1/2 Phase I Toxicology Poster](/content/ism5411_phd1/2_preclinical_toxicology_poster/index.html): PRECLINICAL TOXICOLOGY EVALUATION OF GUT-RESTRICTED PHD1/2 INHIBITOR ISM5411: 13-WEEK ORAL ADMINISTRATION IN RATS AND BEAGLE DOGS (24 words)
- [COVID-19 | Insilico Medicine](/content/ncov-sprint/index.html) (562 words)
- [Biologie Générative | Insilico Medicine](/content/generativebiologics_fr/index.html) (253 words)
- [ISM001-055 Phase2a HRCT Poster](/content/ism001-055_phase2a_hrct_poster/index.html): GENESIS-IPF: Phase 2A Cohort Characteristics And Lung Imaging Indicate Correlates Of Response To ISM001-055 (Rentosertib) In Patients With Idiopathic Pulmonary Fibrosis (23 words)
- [ISM5411, PHD1/2 T-cell Phase I Poster](/content/ism5411_phd1/2_t-cell_phase1_poster/index.html): ISM5411 (ISM012-042), A PHD1/2 INHIBITOR, PREVENTATIVELY AND THERAPUETICALLY MITIGATES T CELL TRANSFER-INDUCED COLITIS IN MICE (21 words)
- [Bioinformatics Hackathon | Insilico Medicine](/content/ism-events/abu-dhabi/hackathon2023/index.html): Participate in the first bioinformatics hackathon in Abu Dhabi organized by Insilico medicine. (543 words)
- [Docuthon Judges | Insilico Medicine](/content/docuthon_cn_judges/index.html) (39 words)
- [Mission | Insilico Medicine](/content/about_fr/index.html) (401 words)
- [IPF – Phase 1 | Insilico Medicine](/content/blog/ipf-phase1/index.html): A Phase 1 Breakthrough in AI Drug Discovery Behind Insilico Medicine’s Potential First-in-Class AI-Discovered and AI-Designed Drug for Idiopathic Pulmonary Fibrosis (961 words)
- [TNIK | Insilico Medicine](/content/pipeline/tnik_tc/index.html) (325 words)
- [Why I Left Big Pharma for AI: Insilico Medicine’s Co-CEO Dr. Feng Ren| Insilico Medicine](/content/ren_co-ceo/index.html): Why I Left Big Pharma for AI: Insilico Medicine’s Co-CEO Dr. Feng Ren (903 words)
- [Research Collaboration Using Insilico Medicine’s AI Yields New Treatment Possibilities for ALS | Insilico Medicine](/content/treatmentals/index.html): Research Collaboration Using Insilico Medicine’s AI Yields New Treatment Possibilities for ALS  (974 words)
- [ReLEHF | Insilico Medicine](/content/blog/relehf/index.html): Reinforcement Learning with Expert Human Feedback (ReLEHF) to Advance Pharmaceutical Generative AI (1,144 words)
- [ISM5411, PHD1/2 Phase I Clinical Poster](/content/ism5411_phd1/2_phase1_clinical_poster/index.html): ISM5411, A NOVEL GUT-RESTRICTED PHD1/2 INHIBITOR FOR INFLAMMATORY BOWEL DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PK PROFILES (31 words)
- [ISM001-055 EFFICACY](/content/poster_ism001-055_efficacy/index.html): Rentosertib (formerly INS018_055), A Novel AI-Designed TNIK Inhibitor, Improves Lung Function In Patients With Idiopathic Pulmonary Fibrosis: Results From A Randomized, Placebo-controlled Phase 2a Study (29 words)
- [Drug Discovery Record | Insilico Medicine](/content/blog/pccfosun/index.html): Setting Drug Discovery Speed Record with a Milestone in Cancer  (1,131 words)
- [ISM001-055 BIOMARKER](/content/poster_ism001-055_biomarker/index.html): Antifibrotic And Anti-inflammatory Signatures In Idiopathic Pulmonary Fibrosis Patients Treated With Rentosertib (INS018_055), An AI-discovered TNIK Inhibitor, In A 12-week Phase 2a Study (29 words)
- [媒體工具包 | Insilico Medicine](/content/mediakit_tc/index.html) (155 words)
- [Insilico & Nanome Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19](/content/insiliconanome/index.html): Insilico & Nanome Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19 (838 words)
- [IMGAIA | Insilico Medicine](/content/imgaia/index.html) (135 words)
- [UEG WEEK 2025 Posters | Insilico Medicine](/content/ueg2025/index.html) (10 words)
- [The next step in AI drug discovery: Robots| Insilico Medicine](/content/roboticslab/index.html): Insilico Medicine to launch fully automated AI-driven robotics lab (754 words)
- [USP1 | Insilico Medicine](/content/pipeline/usp1_tc/index.html) (196 words)
- [Releases | PandaOmics](/content/pandaomics/help/releases/index.html) (1,200 words)
- [GENESIS-IPF HRCT 2025 Poster | Insilico Medicine](/content/genesis-ipf_hrct_2025/index.html) (5 words)
- [TEAD | Insilico Medicine](/content/pipeline/tead_tc/index.html) (134 words)
- [Rare Diseases | Insilico Medicine](/content/blog/rare-diseases/index.html): Insilico Medicine Is Using Generative AI to Design New Drugs For Rare Diseases (669 words)
- [Careers | Insilico Medicine](/content/careers/index.html): Working at Insilico Medicine (1,649 words)
- [Design Resources | Insilico Medicine](/content/design-resources/index.html) (289 words)
- [Prioritization Scores | PandaOmics](/content/pandaomics/help/scores/index.html) (1,327 words)
- [QPCTL | Insilico Medicine](/content/pipeline/qpctl_tc/index.html) (132 words)
- [Blog | Insilico Medicine](/content/blog/index.html) (506 words)
- [ENPP1 | Insilico Medicine](/content/pipeline/enpp1_tc/index.html) (187 words)
- [Druggability Filters | PandaOmics](/content/pandaomics/help/filters/index.html) (861 words)
- [Target ID | PandaOmics](/content/pandaomics/help/target_id/index.html) (599 words)
- [Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis](/content/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr.html) (2,362 words)
- [Chemistry42 at NVIDIA GTC 2021CN | Insilico Medicine](/content/blog_cn/gtc21/index.html): Insilico Medicine to present Chemistry42 and the end-to-end drug discovery case study at NVIDIA GTC 2021 (323 words)
- [Chemistry42 at NVIDIA GTC 2021](/content/blog/gtc21/index.html): Insilico Medicine to present Chemistry42 and the end-to-end drug discovery case study at NVIDIA GTC 2021 (328 words)
- [Compound ID | PandaOmics](/content/pandaomics/help/compound_id/index.html) (746 words)
- [CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World| Insilico Medicine](/content/ai100/index.html): CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World (423 words)
- [Comparison Creation | PandaOmics](/content/pandaomics/help/comparison/index.html) (797 words)
- [Gene-Disease Report | PandaOmics](/content/pandaomics/help/gene-disease_report/index.html) (280 words)
- [Academic Grant Application | Insilico Medicine](/content/academic-grant-application/index.html): Insilico Medicine now has an Academic Grant Application (1,124 words)
- [Genetic Data | PandaOmics](/content/pandaomics/help/genetic_data/index.html) (365 words)
- [Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025’s Largest Hong Kong Biotech IPO](/content/news/p010170up1-insilico-medicine-lists-on-hong-kong-sto.html) (2,183 words)
- [Press Releases | Insilico Medicine](/content/news/index.html) (495 words)
- [英矽智能发布2025年度业绩，重新定义AI制药价值兑现逻辑](/content/news_sc/xodt8x3rc1-2025ai/index.html) (53 words)
- [Blog CN | Insilico Medicine](/content/blog_cn/index.html) (211 words)
- [Indication Prioritization | PandaOmics](/content/pandaomics/help/indication-prioritization/index.html) (485 words)
- [KAT6 | Insilico Medicine](/content/pipeline/kat6_tc/index.html) (137 words)
- [主頁  | Insilico Medicine](/content/main_tc/index.html) (46 words)
- [Custom Data Upload | PandaOmics](/content/pandaomics/help/dataset/index.html) (670 words)
- [Dedicated Pages | PandaOmics](/content/pandaomics/help/dedicated_pages/index.html) (66 words)
- [ChatPandaGPT | PandaOmics](/content/pandaomics/help/chatpandagpt/index.html) (348 words)
- [MAT2A | Insilico Medicine](/content/pipeline/mat2a_tc/index.html) (136 words)
- [CO2 Capture](/content/interactive/co2/index.html) (513 words)
- [Data Manager | PandaOmics](/content/pandaomics/help/data_manager/index.html) (99 words)
- [團隊 | Insilico Medicine](/content/team_tc/index.html) (63 words)
- [TNIK | Insilico Medicine](/content/pipeline_target_targetx/index.html) (816 words)
- [Publications | Insilico Medicine](/content/publications/index.html) (375 words)
- [Rentosertib](/content/interactive/drugs/rentosertib/index.html) (297 words)
- [Comparison Interpretation | PandaOmics](/content/pandaomics/help/comparison_summary/index.html) (78 words)
- [Agrochemistry](/content/interactive/agrochemistry/index-2.html) (551 words)
- [TEAD](/content/interactive/drugs/tead/index.html) (242 words)
- [Experimental Group Setup | PandaOmics](/content/pandaomics/help/group/index.html) (428 words)
- [Oils and Lubricants](/content/interactive/oils/index.html) (411 words)
- [H2 storage](/content/interactive/h2/index.html) (509 words)
- [Metadata Analysis | PandaOmics](/content/pandaomics/help/metadata_analysis/index.html) (87 words)
- [Knowledge Graph | PandaOmics](/content/pandaomics/help/knowledge_graph/index.html) (193 words)
- [Meta-Analysis | PandaOmics](/content/pandaomics/help/meta-analysis/index.html) (158 words)
- [Affected Pathways | PandaOmics](/content/pandaomics/help/pathways/index.html) (123 words)
- [使命 | Insilico Medicine](/content/about_tc/index.html) (38 words)
- [聯絡我們 | Insilico Medicine](/content/contact_tc/index.html) (65 words)
- [Science MMAI Gym](/content/mmai/index.html): Take your AI model to Science MMAI Gym (498 words)
- [Differentially Expressed Genes | PandaOmics](/content/pandaomics/help/genes/index.html) (183 words)
- [管線 | Insilico Medicine](/content/pipeline_tc/index.html): 多元化管線 使用 PHARMA.AI 發現 (84 words)
- [QPCTL](/content/interactive/drugs/qpctl/index.html) (274 words)
- [OMICs Research Workflow | PandaOmics](/content/pandaomics/help/workflow/index.html) (198 words)
- [KAT6](/content/interactive/drugs/kat6/index.html) (281 words)
- [Garutadustat](/content/interactive/drugs/garutadustat/index.html) (176 words)
- [USP1](/content/interactive/drugs/usp1/index.html) (271 words)
- [PHD1/2 CKD](/content/interactive/drugs/phd-ckd/index.html) (177 words)
- [Insilico Medicine Releases Positive Profit Alert for the First Half of 2026](/content/news/6f8yhr6sl1-insilico-medicine-releases-positive-prof.html) (1,505 words)
- [Sustainability Consortium](/content/interactive/sustainability/index.html) (51 words)
- [Targeting the $100 Billion Market: Insilico Medicine Nominates AI-driven Novel PCC ISM9528 for Pain Management](/content/news/3hbxchsjl1-targeting-the-100-billion-market-insilic.html) (1,062 words)
- [Large Language of Life Models](/content/interactive/longevity/lllms/index.html) (217 words)
- [Insilico Medicine to Present 3 Abstracts at the 2026 Crohn’s & Colitis Congress Highlighting Clinical, Preclinical Safety, and Efficacy Data for ISM5411, a Novel Gut-Restricted PHD1/2 Inhibitor](/content/news/28ohjfj6u1-insilico-medicine-to-present-3-abstracts.html) (867 words)
- [ISM Structure](/content/mindmap/index.html) (11 words)
- [Request access | PandaOmics](/content/access/request_demo/index.html) (49 words)
- [Drug Discovery and Development](/content/interactive/drugs/index.html) (10 words)
- [新聞發布 | Insilico Medicine](/content/news_tc/index.html) (20 words)
- [3D](/content/3d/index.html) (3 words)
- [Hallmarks of Aging](/content/interactive/longevity/hoa/index.html) (135 words)
- [職業發展 | Insilico Medicine](/content/careers_tc/index.html) (6 words)
- [Events | Insilico Medicine](/content/events/index.html) (75 words)
- [Nature Reviews Drug Discovery | Target Identification and Assessment in the Era of AI](/content/news/3fymrymsu1-nature-reviews-drug-discovery-target-ide.html) (1,313 words)
- [ENPP1](/content/interactive/drugs/enpp1/index.html) (295 words)
- [Up to 31.3% Body Weight Loss, Insilico Medicine Nominates AI-Powered GIPR Antagonist ISM0676 as Preclinical Candidate, Showing Synergistic Efficacy in Combination Therapy](/content/news/7niehprgd1-up-to-313-body-weight-loss-insilico-medi.html) (784 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972970-955997014421-2023-technology-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972970-833955589331-2024-another-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972970-168004075521-2023-another-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972970-786813826641-2024-platform-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972970-407768442311-2023-development-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972971-143815165781-2022-development-call/index.html) (1 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972971-259383193751-2022-technology-call/index.html) (1 words)
- [Insilico and TaiGen achieve milestone in collaboration: Out-licensed CKD anemia candidate ISM4808 completes first human enrollment and dosing in Phase I clinical trial](/content/news/7bj17u8sd1-insilico-and-taigen-achieve-milestone-in.html) (534 words)
- [Authentication required](/content/ir/investor-calendar_cn/tproduct/660972971-523401359671-2022-platform-call/index.html) (1 words)
- [Authentication required](/content/ir/corporate-governance_cn/tproduct/660972498-111943386701-4-shareholder-communication-policy.html) (1 words)
- [Authentication required](/content/ir/corporate-governance_cn/tproduct/660972498-592170327041-2-procedures-for-shareholders-to-propose.html) (1 words)
- [Authentication required](/content/ir/corporate-governance_cn/tproduct/660972498-553036680811-1-list-of-directors-and-their-roles-and.html) (1 words)
- [Authentication required](/content/ir/corporate-governance_cn/tproduct/660972498-693730847481-5-sixth-amended-and-restated-memorandum.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-136919361961-monthly-return-of-equity-issuer-on-movem.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-889289060111-profit-alert/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-271286801461-date-of-board-meeting/index.html) (1 words)
- [Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery](/content/news/4ifuiaal01-insilico-medicine-announces-collaboratio.html) (480 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-726795909361-voluntary-announcement-businesscooperati.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-974929703551-annual-results-announcement/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-980585618991-voluntary-announcement-marketing-applica.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-498696633431-interim-results-announcement.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-855734354981-annual-report/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-289721872311-annual-results-announcement/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-522129163121-interim-report/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971545-821695376851-announcement-of-interim-results-for-the.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-191138152141-esg-report/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-257959110641-esg-report/index.html) (1 words)
- [Authentication required](/content/ir/information-disclosure_cn/tproduct/660971542-357805452381-annual-report/index.html) (1 words)

## About Pages

- [Team | Insilico Medicine](/content/team/index.html) (960 words)
- [Mission | Insilico Medicine](/content/about/index.html) (259 words)
- [Contact us | Insilico Medicine](/content/contact/index.html) (206 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives